Novel PdPtCu Nanozymes for Reprogramming Tumor Microenvironment to Boost Immunotherapy Through Endoplasmic Reticulum Stress and Blocking IDO-Mediated Immune Escape

Small. 2023 Nov;19(44):e2303596. doi: 10.1002/smll.202303596. Epub 2023 Jul 2.

Abstract

Breaking immunosuppressive tumor microenvironment (TME) has unique effects on inhibiting tumor growth and recurrence. Here, an endoplasmic reticulum (ER) targeted PdPtCu nanozyme (PNBCTER ) is prepared to boost immunotherapy. First, PNBCTER has three kinds of enzyme activities, including catalase (CAT), glutathione oxidase (GSHOx), and peroxidase (POD)-like activities, which can reshape the TME. Second, PNBCTER kills tumor cells by photodynamic therapy (PDT) and photothermal therapy (PTT). Third, guided by TER , PNBCTER not only realizes the combination therapy of PDT, PTT and chemodynamic therapy (CDT), but also damages the ER of tumor cells and actives antitumor immune response, which breaks through the immune blockade of TME. Finally, the NLG919 blocks the tryptophan/kynurenine immune escape pathway and reverses the immunosuppressive TME. The strategy that reshaping the TME by enzyme catalysis and breaking immunosuppression provides a novel way for the application of combination therapy in tumor.

Keywords: combination therapy; endoplasmic reticulum targeting; immune checkpoint inhibitors; immunogenic cell death; noble metal nanozyme.

MeSH terms

  • Catalysis
  • Cell Line, Tumor
  • Combined Modality Therapy
  • Endoplasmic Reticulum Stress
  • Humans
  • Immunotherapy
  • Neoplasms*
  • Tumor Microenvironment*